SSSriram Seshadri

Sriram Seshadri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sriram Seshadri has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hierarchically engineered injectable hydrogels loaded with polyphenol for enhanced wound healing and tissue regeneration

    by Prasanna Kumari Barani, Indu Yadav, Manisha Meena, Ankur Singh, Aneri Joshi, Devanshi Gajjar, Sriram Seshadri, Dhiraj Bhatia, Mukesh Dhanka

    The healing of deep wounds is severely impeded by the converging pathophysiology of persistent inflammation, oxidative stress, bacterial infection, and many other factors that necessitate an ideal solution that simultaneously targets multiple barriers to accelerate the healing of wounds. Here, we report SCLP, a multifunctional, dynamically cross-linked hierarchical hydrogel network synthesised through the strategic integration of a lab-synthesised spermine–gellan gum conjugate (S), chondroitin sulfate (C), LAPONITE®–polyethyleneimine (L–PEI) nanohybrids, and the plant-derived polyphenol protocatechualdehyde (P). The materials chemistry of SCLP relies on stable amide conjugation, polyelectrolyte complexation, and reversible Schiff-base bridging to mimic the extracellular matrix (ECM) while providing superior tissue adhesiveness and shear-thinning injectability. Physicochemical evaluations indicate robust cross-linking, an interconnected porous framework, improved mechanical reliability, and controlled biodegradation. Furthermore, the hydrogel exhibits synergistic antioxidant, anti-inflammatory, and potent antibacterial properties through the rational assembly of bioactive moieties. In vitro studies show steady exudate absorption, hemocompatibility, enhanced fibroblast viability, and the inhibition of bacterial biofilms. In vivo full-thickness wound models display accelerated wound closure and significant granulation tissue formation, without organ toxicity or adverse skin reactions. Collectively, SCLP offers a next-generation bioactive platform that simultaneously addresses the multifaceted barriers to wound healing while outperforming conventional dressings and monofunctional materials, thereby setting a new standard in effective wound care.


  • Open Access

    Programmable DNA-Silk fibroin hydrogel scaffold with temporal mechanical reinforcement for mesenchymal stem cells differentiation and accelerated wound healing in a full-thickness skin defect mice model

    by Nihal Singh, Bhagyesh Parmar, Aneri Joshi, Devanshi Gajjar, Vivek Kashyap, Raghu Solanki, Ankur Singh, Seshadri Sriram, Dhiraj Bhatia

    DNA-based hydrogels have attracted significant attention in biomedical applications due to their programmability, biocompatibility, and tunable functionalities. However, their clinical translation is hindered by high synthesis costs, limited mechanical strength, poor stability, and complex synthesis protocols. In this work, we present a novel DNA-silk fibroin hybrid hydrogel that overcomes these limitations by combining the unique biofunctionality of DNA with the superior mechanical and chemical properties of silk fibroin. Salmon-derived DNA, an abundant and low-cost source, was incorporated with silk fibroin to form hybrid networks via a simple, scalable process. Silk fibroin served as a robust scaffold, enhancing mechanical strength, controlling degradability, and improving structural stability, while the entangled DNA-silk network reduced rapid DNA degradation. The resulting hybrid hydrogel demonstrated temporal mechanical reinforcement and prolonged stability, with in vitro studies demonstrating that the developed hybrid hydrogel enhanced the chondrogenic and osteogenic differentiation of Infrapatellar Fat Pad Mesenchymal Stem Cells (IFP-MSCs). Additionally, hemostatic and in vivo studies demonstrated the potential of DNA-silk fibroin hydrogel as a promising biomaterial for rapid hemostasis and accelerated wound healing. Overall, the developed DNA-silk fibroin hybrid hydrogel offers strong potential for mesenchymal tissue engineering, hemostatic adjuvant and wound healing.


  • Structure based in-silico study for the design of novel Curcumin analogs against Farnesoid-X-receptor (FXR) receptor as hepatoprotective agents

    by Aneri Joshi, Vivek K. Vyas, Sriram Seshadri

    Farnesoid X receptor (FXR) is a multifunctional nuclear receptor that plays an essential role in liver regeneration, maintaining liver homeostasis, counterregulation of hepatic inflammation, and regulation of immune response. As the expression of FXR is downregulated during the development of liver cancer, there may be a loss of function, and hence, designing a novel therapeutic can help overcome this issue. Curcumin, a polyphenol extracted from the rhizome of Curcuma longa L., has multiple, molecular targets which make it a suitable ligand molecule as it acts as an anti-cancer, anti-inflammatory, and antioxidant. Despite its efficacy, it hinders applicability due to its low bioavailability, short half-life, rapid metabolism, and elimination. Curcumin analogs can be designed by incorporating fluoro atoms containing groups as they can improve metabolic stability, better physicochemical properties, and increased binding affinity. The study includes molecular docking of designed curcumin analogs with the FXR receptor (6HL1) and understanding their docking energy, interactions, molecular dynamic simulations, and ADMET properties. From 18 designed analogs, the best docking score was found in the 13d analog, which is − 10.228 kcal/mol. Further molecular dynamic simulation of the 6HL1-13d complex was performed to check its structural stability, and interactions, identifying some common amino acids such as TYR361 and MET265, which are present during both molecular docking and simulations.

  • Open Access

    Translating the vaginal microbial landscape: a connecting link between bacterial vaginosis and preeclampsia

    by Devanshi Gajjar, Sriram Seshadri

    The human vaginal microbiome plays a pivotal role in maintaining female reproductive health through its Lactobacillus-dominated microbial ecology. These bacteria contribute to the acidic pH of the vagina by producing lactic acid, ultimately preventing the colonization of pathogens. Additionally, they produce bacteriocins and hydrogen peroxide, which are detrimental to other microorganisms. Human vaginal microbiota is subjected to alterations with advancement in age, hormonal status, puberty, menstruation cycle, pregnancy and gestation, vaginal tract diseases, exposure to antibiotics, etc. Diet, lifestyle factors, obesity, and gestational diabetes are also reported to cause a shift in vaginal microbiota. This review thoroughly illustrates the perpetually changing dynamics of vaginal microbiota throughout women’s lives, as well as focuses on the impact of dysbiosis in bacterial vaginosis. More emphasis is given on immunological changes observed during bacterial vaginosis, mainly IL-1β, and its involvement in the development of preeclampsia. Thereby, this review highlights a mechanistic link between lower genital tract disease, bacterial vaginosis, and a hypertensive disorder of pregnancy, preeclampsia, via IL-1β–ROR-γt–Th17 axis, which is regulated by vitamin D, with a suggestion on how shifts in vaginal microbial community may pose a risk for preeclampsia.


  • Open Access

    Understanding the implications of microplastics on maternal health during pregnancy, gut dysbiosis, and gestational diabetes mellitus

    by Sriram Seshadri

    The pollution due to plastic waste has become a major environmental and health threat worldwide. Microplastics (MPs) enter the food pyramid from the sea salt, drinking water, and by the consumption of marine animals. Micro and nanoplastics upon ingestion by both humans and animals, can efficiently cross the epithelial barriers. Exposure to MPs results in changes leading to metabolic, oxidative effects, along neurotoxic as well as reproductive toxicity, and probable carcinogenic outcomes. MPs comprise additives which may play a key role as endocrine disruptors, interfering with the body’s hormonal balance and potentially leading to a wide range of health complications in all age groups individuals including developing fetuses. MPs cause microbial dysbiosis, leading to and independently resulting in gut inflammation and dysfunction. A range of health complications, such as gut-associated disorders, inflammation, and other chronic diseases, are associated with gut disruption. In addition, circulating MPs possessing the potential to induce chronic inflammation cross the blood–brain barrier, thereby impacting through the gut-brain axis and potentially leading to neuroinflammatory effects. Exposure to MPs inhibits acetylcholinesterase activity and alters acetylcholine levels, the key contributors associated with behavior. Women’s gestational diabetes mellitus (GDM) is characterized by an increased presence of Ruminococcaceae, Parabacteroides distasonis, and Prevotella. These microbial diversities are linked to metabolic pathways involved in insulin signaling and carbohydrate metabolic pathways. MPs may be increasing some genera of the human gut microbiota, especially the Roseburia, Clostridium, and Prevotella. The effect of MPs on microbial dysbiosis, maternal health, and their potential metabolic repercussions needs urgent focus. The current review tries to address the effect of MPs on the microbial dysbiosis, specifically the maternal microflora and its impact leading to GDM.


  • Postbiotic potential of SCFAs on metaflammation and gut microbiota alteration in diabetes

    by Dipeeka K Mandaliya, Sweta Patel, Sriram Seshadri

    Gut microbiota regulate host metabolism via its fermentation products, mainly short-chain fatty acids (SCFAs), i.e., acetate, propionate, and butyrate. Although butyrate is studied for its anti-inflammatory, anti-obesity, and anti-diabetic effects, propionate alone and in combination with acetate or butyrate is not well reported. In this study, we have shown the combinatorial effect of propionate with acetate or butyrate in the regulation of diabetes characteristics, liver metabolism, and inflammation via SCFA receptors and gut microbiota modulation. Diabetes was induced by high-fat diet administration for 4 months and was followed by oral administration of SCFAs for 1 month. Although propionate and butyrate alone showed reduced diabetic characteristics, a combination of propionate with acetate or butyrate more significantly regulated insulin downstream pathway molecules, i.e., liver X receptor (LXR), sterol regulatory element binding protein 1c (SREBP1c), glucose transporter type 4 (GLUT4), and peroxisome-proliferator-activated receptor alpha (PPARα), and enhanced the expression of SCFA receptors, i.e., G-protein-coupled receptor 41 (GPR41), GPR43, and GPR109 in the liver. They increased microbial richness and evenness along with the restoration of probiotic bacterial strains, healthy bacteria, as well as butyrate producers, mainly, Lactobacillus, Oscillospira, Barnesiella, Rikenellaceae_RC9_gut_group and Lachnospiraceae_NK4B4_group, Roseburia, Eubacteria, and Akkermensia. In conclusion, propionate in the presence of acetate or butyrate exerts beneficial effects on liver metabolism and inflammation via SCFA receptor modulation and gut microbiota alteration in the case of HFD-induced diabetic mice. Graphical abstract


  • Open Access

    A dynamically crosslinked, self-adapting, injectable gelatin–chondroitin sulfate hydrogel with antibacterial and antioxidant properties for treatment of deep and irregular wounds

    by Aniruddha Dan, Devanshi Sharma, Hemant Singh, Sunny Kumar, Zeel Bhatia, Shabir Hassan, Sriram Seshadri, Mukesh Dhanka

    A self-adaptable, injectable hydrogel for irregular shaped wound healing, composed of gelatin and chondroitin sulfate, containing tannic acid and in situ synthesized silver nanoparticles.


  • Chitosan: Microsphere Formulation and Characterization for Slow - Release Prebiotic Activities in Gut Microbiota Remodelling

    by Sunny Kumar, Zeel Bhatia, Sriram Seshadri

    Introduction: Chitosan is a biocompatible, mucoadhesive, and biodegradable polymer widely used for various purposes due to its biological activity and safety. The current study aimed to formulate Chitosan microspheres and conduct an in-vitro evaluation of their cytotoxicity. The concept is focused on targeted gut delivery and biological activities in gut microbiota remodelling. Methods: The formulations were comprehensively characterized, encompassing SEM for surface morphology, particle size analysis, and FT-IR for structural understanding. Along with biological activity and cytotoxicity studies, dissolution efficiency was considered to understand release kinetics potential and accelerated stability studies to predict formulation shelf-life. Results: The formulation showed smooth spherical surface morphology with an average size range of 30.0 ± 5.0 μm and a charge of 20.35 ± 0.35 mV. Further, functional and thermal properties were determined using FT-IR and DSC, respectively. The microspheres showed a potent prebiotic potential in gut flora isolated and processed from a faecal sample of Wistar rats with prolonged release characteristics in the dissolution study. A cytotoxicity study using rat intestinal epithelial cells (IEC6) indicated that 40 mg /kg of microspheres could be considered an optimal dose for an in-vivo study. Conclusion: The formulation demonstrated promising pharmaceutical applicability due to its potential prebiotic nature and slow release into the gut environment. After a thorough in vivo study, the microspheres can be broadly used to restore gut dysbiosis due to their potential prebiotic activities in various diseases and disorders, including but not limited to obesity, type-2 diabetes, cardiometabolic disease, and non-alcoholic fatty liver disease.


  • Design and evaluation of potent multiepitope broad spectrum DNA and protein vaccine candidates against leptospirosis

    by Anita Chauhan, Dhwani Jhala, Ritik Thumar, Kopal Kapoor, Aneri Joshi, Devanshi Gajjar, Sriram Seshadri, Satyamitra Shekh, Chaitanya Joshi, Amrutlal Patel